Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
This grant funds innovative technologies to improve handling and quality of biospecimens for cancer research and care, aiming to enhance downstream analyses and address pre-analytical degradation issues.
Browse similar grants
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: April 4, 2025 | October 3, 2025 | December 9, 2025 (current closing date)
Funding Amounts: Up to $150,000/year (direct costs) | Max project period: 3 years | Estimated 4 awards | Total program funding: $1,000,000
Summary: Supports early-stage, high-risk/high-impact technology development to improve the quality and handling of biospecimens for cancer research and clinical care.
Key Information: Clinical trials are not allowed; applications must focus on technical innovation, not biological hypotheses.
Description
This opportunity, offered by the National Cancer Institute (NCI) under the NIH, seeks exploratory research projects for the early-stage development of innovative technologies to improve the quality, handling, collection, processing, preservation, or storage of cancer-relevant biospecimens and their derivatives. The goal is to support the creation of tools, devices, assays, instrumentation, and methods that maximize or assess the quality and utility of biological samples used in cancer research or clinical care, with emphasis on overcoming pre-analytical degradation and enabling advances in cancer biology, early detection, diagnosis, treatment, epidemiology, and addressing health disparities. Projects must be highly innovative, high-risk/high-reward, and focused on technical development rather than the pursuit of specific biological or clinical hypotheses.
